JP2024533487A5 - - Google Patents

Info

Publication number
JP2024533487A5
JP2024533487A5 JP2024516396A JP2024516396A JP2024533487A5 JP 2024533487 A5 JP2024533487 A5 JP 2024533487A5 JP 2024516396 A JP2024516396 A JP 2024516396A JP 2024516396 A JP2024516396 A JP 2024516396A JP 2024533487 A5 JP2024533487 A5 JP 2024533487A5
Authority
JP
Japan
Prior art keywords
polypeptide
fusion polypeptide
ferritin
self
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024516396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533487A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2022/051360 external-priority patent/WO2023035083A1/en
Publication of JP2024533487A publication Critical patent/JP2024533487A/ja
Publication of JP2024533487A5 publication Critical patent/JP2024533487A5/ja
Pending legal-status Critical Current

Links

JP2024516396A 2021-09-13 2022-09-13 最適化されたＭｕｌｔａｂｏｄｙ構築物、組成物、及び方法 Pending JP2024533487A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163243402P 2021-09-13 2021-09-13
US63/243,402 2021-09-13
PCT/CA2022/051360 WO2023035083A1 (en) 2021-09-13 2022-09-13 Optimized multabody constructs, compositions, and methods

Publications (2)

Publication Number Publication Date
JP2024533487A JP2024533487A (ja) 2024-09-12
JP2024533487A5 true JP2024533487A5 (cg-RX-API-DMAC7.html) 2025-09-24

Family

ID=85506121

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024516396A Pending JP2024533487A (ja) 2021-09-13 2022-09-13 最適化されたＭｕｌｔａｂｏｄｙ構築物、組成物、及び方法

Country Status (9)

Country Link
US (1) US20240400704A1 (cg-RX-API-DMAC7.html)
EP (1) EP4402179A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024533487A (cg-RX-API-DMAC7.html)
KR (1) KR20240102943A (cg-RX-API-DMAC7.html)
CN (1) CN118488971A (cg-RX-API-DMAC7.html)
AU (1) AU2022343032A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231173A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024003140A (cg-RX-API-DMAC7.html)
WO (1) WO2023035083A1 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020320459A1 (en) * 2019-08-01 2022-03-03 The Governing Council Of The University Of Toronto Multi-valent and multi-specific nanoparticle platforms and methods
CN117157328A (zh) * 2021-01-28 2023-12-01 儿童医院 Multabody构建体、组合物和方法

Similar Documents

Publication Publication Date Title
JP2022544771A5 (cg-RX-API-DMAC7.html)
JP2022535924A5 (cg-RX-API-DMAC7.html)
US20170210818A1 (en) Constant region antibody fusion proteins and compositions thereof
JP2021514618A5 (cg-RX-API-DMAC7.html)
JP2021503455A5 (cg-RX-API-DMAC7.html)
JP2020114210A5 (cg-RX-API-DMAC7.html)
JP2019502694A5 (cg-RX-API-DMAC7.html)
US20180079798A1 (en) Trispecific binding molecules for treating hbv infection and associated conditions
JP2021500852A5 (cg-RX-API-DMAC7.html)
CN107206077A (zh) 靶向g‑蛋白偶联受体的抗体和使用方法
JP2021522162A5 (cg-RX-API-DMAC7.html)
WO2019091436A1 (zh) 4-1bb抗体及其制备方法和应用
JP2021159081A5 (cg-RX-API-DMAC7.html)
JP2011501951A5 (cg-RX-API-DMAC7.html)
JP2017504578A5 (cg-RX-API-DMAC7.html)
CA3173414A1 (en) Pd-1 agonist multimeric binding molecules
JP2011526249A5 (cg-RX-API-DMAC7.html)
JP2026004299A5 (cg-RX-API-DMAC7.html)
JP2024544559A5 (cg-RX-API-DMAC7.html)
JP2025541367A (ja) 多価および多重特異性サイトカインアンタゴニスト
JP2024533487A5 (cg-RX-API-DMAC7.html)
WO2025162161A1 (zh) 特异性结合pd-1的单克隆抗体及其医药用途
JP2024533485A5 (cg-RX-API-DMAC7.html)
JP2022532994A5 (cg-RX-API-DMAC7.html)
RU2024109942A (ru) Оптимизированные конструкции multabody, композиции и способы